Vimta Labs Share Price
Vimta Labs Ltd.
Performance of Vimta Labs Shares 
Open Price
Prev. Close
Volume
Value
About Vimta Labs
Vimta Labs is a leading provider of analytical, testing and research services for the pharmaceutical, biopharmaceutical, and life sciences industries. Founded in 1980, the company has been delivering high-quality services to clients globally, helping them to develop, manufacture, and market their products safely and effectively.
Vimta Labs has a state-of-the-art laboratory equipped with the latest analytical and testing technologies, allowing them to perform a wide range of services, including stability studies, method development and validation, raw material testing, and product release testing. The company also provides analytical services for pharmaceutical development, bioequivalence and bioavailability studies, and pharmacokinetic studies.
Vimta Labs has a team of highly qualified scientists and technicians who are dedicated to delivering accurate and reliable results. The company operates with a strong focus on quality and is committed to meeting the highest industry standards. The company is accredited by several national and international organisations, including the World Health Organization (WHO) and the International Conference on Harmonization (ICH).
Vimta Labs has a strong commitment to innovation and continuously invests in research and development to stay ahead of the curve in its field. The company has a dedicated research team developing new testing methods and improving existing ones. The company is also involved in several collaborative research projects with universities and other organisations, strengthening its position as a leader in their field.
In addition to its core services, Vimta Labs also offers consultancy services to clients, providing expert advice on quality management, regulatory affairs, and quality control. The company's consultants have a wealth of experience in the pharmaceutical and biopharmaceutical industries. They can help clients to navigate the complex regulatory landscape and ensure compliance with the relevant regulations and standards.
Whether you're developing a new drug, launching a new product, or looking for expert advice on quality management and regulatory affairs, Vimta Labs is the company to turn to.
Want to stay updated on the latest Vimta Labs Share Price? Invest in Vimta Labs Shares today and reap the benefits of a growing company. Click Here to access our secure online platform and easily make your investment. Take advantage of this opportunity to be a part of a company dedicated to delivering cutting-edge solutions and services in the healthcare sector. Start your investment journey with Vimta Labs now!
Vimta Labs has a state-of-the-art laboratory equipped with the latest analytical and testing technologies, allowing them to perform a wide range of services, including stability studies, method development and validation, raw material testing, and product release testing. The company also provides analytical services for pharmaceutical development, bioequivalence and bioavailability studies, and pharmacokinetic studies.
Vimta Labs has a team of highly qualified scientists and technicians who are dedicated to delivering accurate and reliable results. The company operates with a strong focus on quality and is committed to meeting the highest industry standards. The company is accredited by several national and international organisations, including the World Health Organization (WHO) and the International Conference on Harmonization (ICH).
Vimta Labs has a strong commitment to innovation and continuously invests in research and development to stay ahead of the curve in its field. The company has a dedicated research team developing new testing methods and improving existing ones. The company is also involved in several collaborative research projects with universities and other organisations, strengthening its position as a leader in their field.
In addition to its core services, Vimta Labs also offers consultancy services to clients, providing expert advice on quality management, regulatory affairs, and quality control. The company's consultants have a wealth of experience in the pharmaceutical and biopharmaceutical industries. They can help clients to navigate the complex regulatory landscape and ensure compliance with the relevant regulations and standards.
Whether you're developing a new drug, launching a new product, or looking for expert advice on quality management and regulatory affairs, Vimta Labs is the company to turn to.
Want to stay updated on the latest Vimta Labs Share Price? Invest in Vimta Labs Shares today and reap the benefits of a growing company. Click Here to access our secure online platform and easily make your investment. Take advantage of this opportunity to be a part of a company dedicated to delivering cutting-edge solutions and services in the healthcare sector. Start your investment journey with Vimta Labs now!
Fundamentals of Vimta Labs Shares
Market Cap |
P/E Ratio |
P/B Ratio |
Industry P/E |
|---|---|---|---|
Rs. 706.25 Cr |
23.61 |
2.55 |
143.45 |
ROE |
EPS (TTM) |
Dividend Yield |
Book Value |
|---|---|---|---|
11.40 % |
18.57 |
1.14 % |
120.55 |
FAQ’s
How to buy Vimta Labs Ltd. shares?
All you have to do to buy Vimta Labs Ltd. share is download Nuuu app, create a demat account, and get your KYC documents verified online.
Can I buy Vimta Labs Ltd. shares?
Yes you can buy Vimta Labs Ltd. shares, all you need is to have a verified demat account with Nuuu. And enjoy benefits like free brokerage credits and more.
What is the Market Cap of Vimta Labs Ltd. shares?
As of 26 Mar`23 the Market Cap of Vimta Labs Ltd. is 706.25.
What is the PE and PB ratio of Vimta Labs Ltd. stock?
As of 26 Mar`23 the PE is 23.61 and PB is 2.55.
Vimta Labs - Quaterly Results
Publish Date: 27/10/2022
The September 2022 quarter revenue stood at Rs. 791.32 millions, up 5.94% as compared to Rs. 746.96 millions during the corresponding quarter last year.Net Profit recorded in the quarter ended September 2022 rise to 37.32% to Rs. 130.63 millions compared to R. 95.13 millions in corresponding previous quarter.Operating profit for the quarter ended September 2022 rose to 258.93 millions as compared to 197.58 millions of corresponding quarter ended September 2021.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 791.32 | 746.96 | 5.94 | 1578.16 | 1357.01 | 16.30 | 2759.80 | 2090.51 | 32.02 |
| Other Income | 7.71 | 1.30 | 493.08 | 16.71 | 3.11 | 437.30 | 14.54 | 8.10 | 79.51 |
| PBIDT | 258.93 | 197.58 | 31.05 | 506.39 | 366.26 | 38.26 | 812.26 | 535.01 | 51.82 |
| Interest | 7.99 | 2.42 | 230.17 | 17.43 | 6.74 | 158.61 | 14.96 | 21.67 | -30.96 |
| PBDT | 250.94 | 182.92 | 37.19 | 488.96 | 347.28 | 40.80 | 785.06 | 513.34 | 52.93 |
| Depreciation | 75.32 | 54.80 | 37.45 | 147.39 | 109.73 | 34.32 | 231.58 | 229.37 | 0.96 |
| PBT | 175.62 | 128.12 | 37.07 | 341.57 | 237.55 | 43.79 | 553.48 | 283.97 | 94.91 |
| TAX | 44.99 | 32.99 | 36.37 | 90.64 | 61.37 | 47.69 | 142.90 | 71.37 | 100.22 |
| Deferred Tax | -9.14 | -6.93 | 31.89 | -14.80 | -12.39 | 19.45 | -10.33 | -4.89 | 111.25 |
| PAT | 130.63 | 95.13 | 37.32 | 250.93 | 176.18 | 42.43 | 410.58 | 212.60 | 93.12 |
| Equity | 44.22 | 44.22 | 0.00 | 44.22 | 44.22 | 0.00 | 44.22 | 44.22 | 0.00 |
| PBIDTM(%) | 32.72 | 26.45 | 23.70 | 32.09 | 26.99 | 18.89 | 29.43 | 25.59 | 15.00 |
Vimta Labs - Quaterly Results
Publish Date: 27/01/2023
The revenue zoomed 14.72% to Rs. 764.97 millions for the quarter ended December 2022 as compared to Rs. 666.80 millions during the corresponding quarter last year.A slender decline of -13.91% was recorded to Rs. 99.56 millions from Rs. 115.65 millions in the corresponding previous quarter.OP of the company witnessed a marginal growth to 221.52 millions from 211.09 millions in the same quarter last year.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 764.97 | 666.80 | 14.72 | 2343.13 | 2023.81 | 15.78 | 2759.80 | 2090.51 | 32.02 |
| Other Income | 11.32 | 7.24 | 56.35 | 28.03 | 10.35 | 170.82 | 14.54 | 8.10 | 79.51 |
| PBIDT | 221.52 | 211.09 | 4.94 | 727.91 | 577.35 | 26.08 | 812.26 | 535.01 | 51.82 |
| Interest | 6.53 | 2.48 | 163.31 | 23.96 | 9.22 | 159.87 | 14.96 | 21.67 | -30.96 |
| PBDT | 214.99 | 208.61 | 3.06 | 703.95 | 555.89 | 26.63 | 785.06 | 513.34 | 52.93 |
| Depreciation | 78.03 | 55.41 | 40.82 | 225.42 | 165.14 | 36.50 | 231.58 | 229.37 | 0.96 |
| PBT | 136.96 | 153.20 | -10.60 | 478.53 | 390.75 | 22.46 | 553.48 | 283.97 | 94.91 |
| TAX | 37.40 | 37.55 | -0.40 | 128.04 | 98.92 | 29.44 | 142.90 | 71.37 | 100.22 |
| Deferred Tax | -7.39 | -3.34 | 121.26 | -22.19 | -15.73 | 41.07 | -10.33 | -4.89 | 111.25 |
| PAT | 99.56 | 115.65 | -13.91 | 350.49 | 291.83 | 20.10 | 410.58 | 212.60 | 93.12 |
| Equity | 44.25 | 44.22 | 0.07 | 44.25 | 44.22 | 0.07 | 44.22 | 44.22 | 0.00 |
| PBIDTM(%) | 28.96 | 31.66 | -8.53 | 31.07 | 28.53 | 8.90 | 29.43 | 25.59 | 15.00 |
Vimta Labs informs about unaudited financial results
Publish Date: 27/10/2022
Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, Vimta Labs has informed that it enclosed Standalone and Consolidated Unaudited Financial Results for the second quarter / half year ended 30th September 2022, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website. Abridged financials are being published in the newspapers (copy enclosed). The meeting commenced at 10:00 am and ended at 2:30 pm.
The above information is a part of company’s filings submitted to BSE.
Vimta Labs jumps on reporting 36% rise in Q2 consolidated net profit
Publish Date: 28/10/2022
Total consolidated income of the company increased by 6.61% at Rs 80.62 crore for Q2FY23
Vimta Labs is currently trading at Rs. 401.65, up by 0.80 points or 0.20% from its previous closing of Rs. 400.85 on the BSE.
The scrip opened at Rs. 402.80 and has touched a high and low of Rs. 402.80 and Rs. 380.15 respectively. So far 8838 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 453.00 on 15-Dec-2021 and a 52 week low of Rs. 292.85 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 411.35 and Rs. 380.00 respectively. The current market cap of the company is Rs. 882.06 crore.
The promoters holding in the company stood at 37.46%, while Institutions and Non-Institutions held 2.53% and 60.02% respectively.
Vimta Labs has reported results for second quarter ended September 30, 2022. The company has reported a rise of 37.33% in its net profit at Rs 13.06 crore for the quarter under review as compared to Rs 9.51 crore for the same quarter in the previous year. Total income of the company increased by 6.78% at Rs 79.90 crore for Q2FY23 as compared Rs 74.83 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported rise of 35.63% in its net profit at Rs 13.21 crore for the quarter under review as compared to Rs 9.74 crore for the same quarter in the previous year. Total income of the company increased by 6.61% at Rs 80.62 crore for Q2FY23 as compared Rs 75.62 crore for the corresponding quarter previous year.
Vimta Labs informs about unaudited financial results
Publish Date: 27/01/2023
Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, Vimta Labs has informed that it enclosed Standalone and Consolidated Unaudited Financial Results for the third quarter ended 31st December 2022, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website: https://vimta.comlinvestors/financial-statements/. Abridged financials are being published in the newspapers (copy enclosed). The meeting commenced at 11:30 am and ended at 03:00 pm.
The above information is a part of company’s filings submitted to BSE.
Vimta Labs informs about outcome of board meeting
Publish Date: 27/01/2023
Pursuant to Regulation 30 and 33 of SEBI (Listing obligations and disclosure requirements) 2015, Vimta Labs has informed that it enclosed Standalone and Consolidated Unaudited Financial Results for the third quarter ended 31st December 2022, along with Limited Review Report. Copy of the Unaudited Financial results are also posted on the company’s website, https://vimta.comlinvestors/financial-statements/. Abridged financials are being published in the newspapers.
The above information is a part of company’s filings submitted to BSE.
Board Meeting
Publish Date: 27/01/2023
Quarterly Results
Board Meeting
Publish Date: 27/10/2022
Quarterly Results
Ex Dividend
Publish Date: 16/06/2022
Rs.2.0000 per share(100%)Dividend
Board Meeting
Publish Date: 12/05/2022
Dividend & Audited Results
Board Meeting
Publish Date: 20/01/2022
Quarterly Results
Board Meeting
Publish Date: 23/10/2021
Quarterly Results
Board Meeting
Publish Date: 22/07/2021
Quarterly Results
Ex Dividend
Publish Date: 25/06/2021
Rs.2.0000 per share(100%)Dividend
Board Meeting
Publish Date: 14/05/2021
Employees Stock Option Plan & Dividend & Audited Results
Board Meeting
Publish Date: 23/01/2021
Quarterly Results
Board Meeting
Publish Date: 15/10/2020
Quarterly Results
Vimta Labs reports 36% rise in Q2 consolidated net profit
Publish Date: 28/10/2022
Total consolidated income of the company increased by 6.61% at Rs 80.62 crore for Q2FY23
Vimta Labs has reported results for second quarter ended September 30, 2022.
The company has reported a rise of 37.33% in its net profit at Rs 13.06 crore for the quarter under review as compared to Rs 9.51 crore for the same quarter in the previous year. Total income of the company increased by 6.78% at Rs 79.90 crore for Q2FY23 as compared Rs 74.83 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported rise of 35.63% in its net profit at Rs 13.21 crore for the quarter under review as compared to Rs 9.74 crore for the same quarter in the previous year. Total income of the company increased by 6.61% at Rs 80.62 crore for Q2FY23 as compared Rs 75.62 crore for the corresponding quarter previous year.
Open A Free Demat Account
Sign Up
